Curaleaf

Chronic conditions don’t just affect health — they impact every part of life, including the ability to work. Being excluded from the workforce due to long-term illness can take a serious toll on self-esteem, confidence and overall well-being. Our new research, conducted in collaboration with the Centre for Economics and Business Research, highlights the role that medical cannabis could play in helping many chronically ill people return to work. Key findings: • Around 2.8 million people in the UK are currently locked out of employment due to long-term illness. • 62% report they have exhausted all traditional treatment options. • Since 2018, private prescriptions have already contributed an estimated £283 million in Gross Value Added (GVA) to the UK economy by helping people return to work. • Wider NHS access could help add £13.3 billion to the economy over the next decade. But these opportunities can’t be realised while awareness and access remain limited. 40% of people with long-term health conditions are still unaware that medical cannabis is legally available, and one-third (33%) describe the NHS system as confusing. Yet demand for change is clear: 71% of people affected say medical cannabis should be more widely available if it can help them return to work. That’s why we’re calling for greater NHS access – with clear prescribing pathways and government-funded research – to give patients more choice and, for some, the chance to rejoin the workforce. At its heart, it’s about restoring dignity, independence, and the ability to contribute to society - in whatever way feels meaningful. Fatma, a Curaleaf Clinic patient, put it best: “As someone independent and career-driven, not being able to get out of bed and go to work made me feel as if my identity was being stripped away. I now have the ability to work, lead a team, and regain my independence. Expanding medical cannabis via the NHS would mean greater choice for more people, which can only be a good thing.” The question is no longer if access should expand – but how quickly the UK can put the right systems in place. Read our full report on the blog. https://brnw.ch/21wVGY8 Thank you to Third City and Cebr for their hard work on this report.

Our next phase of innovation – UK launch 🌍 Today, we are proud to announce the UK launch of the Curaleaf Que Medical Inhalation Device (QMID) – the first CE-certified liquid cannabis inhaler available to prescribers and patients.    Via Curaleaf Laboratories, the UK is the first market in our international rollout, with launches planned across the globe in the coming months.   The QMID offers a precise, discreet, and clinically approved way to inhale cannabis-based medicines — addressing one of the biggest unmet needs in the medical cannabis community. In partnership with Jupiter Research, the device is:    ✅ CE-certified, Class IIa approved ✅ Offers consistent, precise timed dosing ✅  Simple, discreet, with a patient-friendly design This milestone reinforces our mission to make safe, regulated cannabis therapies available to patients worldwide. 🔗: https://lnkd.in/e_Z62PJG   #CuraleafInternational #MedicalCannabis #HealthcareInnovation #PatientAccess